File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ginsenosides compound (shen-fu) attenuates gastrointestinal injury and inhibits inflammatory response after cardiopulmonary bypass in patients with congenital heart disease

TitleGinsenosides compound (shen-fu) attenuates gastrointestinal injury and inhibits inflammatory response after cardiopulmonary bypass in patients with congenital heart disease
Authors
Issue Date2005
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jtcvs
Citation
Journal Of Thoracic And Cardiovascular Surgery, 2005, v. 130 n. 2, p. 258-264 How to Cite?
AbstractObjective: This study was undertaken to demonstrate that gastrointestinal mucosal injury occurs during cardiopulmonary bypass in children, increasing systemic inflammatory responses, and to determine whether shen-fu injection (the major components of which are ginsenosides compound, extract of Panax ginseng shown to have antioxidant properties) could attenuate gastrointestinal mucosal injury and subsequent inflammatory responses. Methods: Twenty-four children undergoing heart surgery for congenital heart defects were randomly assigned to groups C (placebo control, n = 12) and G (1.35 mg/kg ginsenosides compound intravenously before and throughout the course of cardiopulmonary bypass, n = 12). Central venous blood samples were taken before cardiopulmonary bypass and at 60 and 120 minutes after aortic declamping (reperfusion). Gastric intramucosal pH was measured by perioperative tonometry. Plasma lipid peroxidation product malondialdehyde, myocardium-specific creatine kinase isoenzyme MB activity, diamine oxidase, lipopolysaccharide, and interleukin 6 were all measured. Results: Significant decrease in gastric intramucosal pH and increase in plasma diamine oxidase were seen during reperfusion in group C, accompanied by increases in plasma levels of malondialdehyde, lipopolysaccharide, interleukin 6, and creatine kinase isoenzyme MB (P < .01 vs before cardiopulmonary bypass). Shen-fu injection significantly attenuated these changes (P < .05). Consequently, fewer patients in group G (2/12) than in group C (7/12) needed postoperative inotropic support. Postoperative intensive care unit stay was shorter in group G than in group C. A tight positive correlation was seen between diamine oxidase and interleukin 6 at 60 minutes after aortic declamping and between diamine oxidase and lipopolysaccharide at 120 minutes after aortic declamping (r = 0.79, P < .0001). Conclusion: Ginsenosides compound may attenuate gastrointestinal injury and inhibit inflammatory response after cardiopulmonary bypass in patients with congenital heart disease. Copyright © 2005 by The American Association for Thoracic Surgery.
Persistent Identifierhttp://hdl.handle.net/10722/147216
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 2.369
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorXia, ZYen_US
dc.contributor.authorLiu, XYen_US
dc.contributor.authorZhan, LYen_US
dc.contributor.authorHe, YHen_US
dc.contributor.authorLuo, Ten_US
dc.contributor.authorXia, Zen_US
dc.date.accessioned2012-05-29T06:00:51Z-
dc.date.available2012-05-29T06:00:51Z-
dc.date.issued2005en_US
dc.identifier.citationJournal Of Thoracic And Cardiovascular Surgery, 2005, v. 130 n. 2, p. 258-264en_US
dc.identifier.issn0022-5223en_US
dc.identifier.urihttp://hdl.handle.net/10722/147216-
dc.description.abstractObjective: This study was undertaken to demonstrate that gastrointestinal mucosal injury occurs during cardiopulmonary bypass in children, increasing systemic inflammatory responses, and to determine whether shen-fu injection (the major components of which are ginsenosides compound, extract of Panax ginseng shown to have antioxidant properties) could attenuate gastrointestinal mucosal injury and subsequent inflammatory responses. Methods: Twenty-four children undergoing heart surgery for congenital heart defects were randomly assigned to groups C (placebo control, n = 12) and G (1.35 mg/kg ginsenosides compound intravenously before and throughout the course of cardiopulmonary bypass, n = 12). Central venous blood samples were taken before cardiopulmonary bypass and at 60 and 120 minutes after aortic declamping (reperfusion). Gastric intramucosal pH was measured by perioperative tonometry. Plasma lipid peroxidation product malondialdehyde, myocardium-specific creatine kinase isoenzyme MB activity, diamine oxidase, lipopolysaccharide, and interleukin 6 were all measured. Results: Significant decrease in gastric intramucosal pH and increase in plasma diamine oxidase were seen during reperfusion in group C, accompanied by increases in plasma levels of malondialdehyde, lipopolysaccharide, interleukin 6, and creatine kinase isoenzyme MB (P < .01 vs before cardiopulmonary bypass). Shen-fu injection significantly attenuated these changes (P < .05). Consequently, fewer patients in group G (2/12) than in group C (7/12) needed postoperative inotropic support. Postoperative intensive care unit stay was shorter in group G than in group C. A tight positive correlation was seen between diamine oxidase and interleukin 6 at 60 minutes after aortic declamping and between diamine oxidase and lipopolysaccharide at 120 minutes after aortic declamping (r = 0.79, P < .0001). Conclusion: Ginsenosides compound may attenuate gastrointestinal injury and inhibit inflammatory response after cardiopulmonary bypass in patients with congenital heart disease. Copyright © 2005 by The American Association for Thoracic Surgery.en_US
dc.languageengen_US
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jtcvsen_US
dc.relation.ispartofJournal of Thoracic and Cardiovascular Surgeryen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAmine Oxidase (Copper-Containing) - Blooden_US
dc.subject.meshAntioxidants - Pharmacology - Therapeutic Useen_US
dc.subject.meshCardiopulmonary Bypass - Adverse Effectsen_US
dc.subject.meshChilden_US
dc.subject.meshCreatine Kinase - Blooden_US
dc.subject.meshCreatine Kinase, Mb Formen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrugs, Chinese Herbal - Pharmacology - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshGastric Mucosa - Drug Effectsen_US
dc.subject.meshGastrointestinal Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshGastrointestinal Diseases - Blood - Etiology - Prevention & Controlen_US
dc.subject.meshHeart Defects, Congenital - Blood - Surgeryen_US
dc.subject.meshHumansen_US
dc.subject.meshHydrogen-Ion Concentration - Drug Effectsen_US
dc.subject.meshInterleukin-6 - Blooden_US
dc.subject.meshIsoenzymes - Blooden_US
dc.subject.meshLipopolysaccharides - Blooden_US
dc.subject.meshMaleen_US
dc.subject.meshMalondialdehyde - Blooden_US
dc.titleGinsenosides compound (shen-fu) attenuates gastrointestinal injury and inhibits inflammatory response after cardiopulmonary bypass in patients with congenital heart diseaseen_US
dc.typeArticleen_US
dc.identifier.emailXia, Z:zyxia@hkucc.hku.hken_US
dc.identifier.authorityXia, Z=rp00532en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.jtcvs.2005.02.046en_US
dc.identifier.pmid16077384-
dc.identifier.scopuseid_2-s2.0-23044510604en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23044510604&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume130en_US
dc.identifier.issue2en_US
dc.identifier.spage258en_US
dc.identifier.epage264en_US
dc.identifier.isiWOS:000231069700005-
dc.publisher.placeUnited Statesen_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats